Combination treatments for unresectable liver cancer study
Part of Cancer, Digestive system clinical trials.
This study looks at combining different treatments (local therapies, targeted therapy, and immunotherapy) for people with liver cancer that cannot be removed by surgery. The goal is to see how safe and effective these combinations are for a broad group of patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 years old or older.
- You need a confirmed diagnosis of hepatocellular carcinoma (HCC, a type of liver cancer).
- Your liver cancer must be at an early to intermediate stage (CNLC stage I, II, or IIIA).
- A team of doctors must have determined that your cancer cannot be surgically removed.
- Your cancer must not have spread to other parts of the body (no extrahepatic metastasis).
- You cannot have certain severe blood clots in the liver's major veins (Cheng's type IV portal vein or type II/III inferior vena cava).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well combining local treatments with targeted drugs and immunotherapy works for patients with liver cancer who are waiting for a transplant. It aims to see if this approach is safe and helps control the cancer.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.